A5055207502- Atrial Fibrillation Management and Outcomes
- Health Systems, Economic Evaluations, Quality of Life
- Venous Thromboembolism Diagnosis and Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Peripheral Artery Disease Management
- Cardiac Arrhythmias and Treatments
- Pharmaceutical Economics and Policy
- Coronary Interventions and Diagnostics
- Cerebrovascular and Carotid Artery Diseases
- Acute Ischemic Stroke Management
- Meta-analysis and systematic reviews
- Pharmaceutical industry and healthcare
- Cardiac Valve Diseases and Treatments
- Medication Adherence and Compliance
- Health disparities and outcomes
- Smoking Behavior and Cessation
- Global Public Health Policies and Epidemiology
- Diagnosis and Treatment of Venous Diseases
- Statistical Methods in Clinical Trials
- Musculoskeletal pain and rehabilitation
- Cardiac Health and Mental Health
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Cardiac, Anesthesia and Surgical Outcomes
- Economic and Financial Impacts of Cancer
- Colorectal Cancer Surgical Treatments
Bayer (United Kingdom)
2018-2022
Bayer (Germany)
2016-2020
Bayer (France)
2018-2020
Bayer (United States)
2020
Pfizer (United Kingdom)
2012
Health Economics and Outcomes Research (United Kingdom)
2010
Little data exists regarding the effectiveness and safety of rivaroxaban or apixaban versus warfarin in nonvalvular atrial fibrillation (NVAF) patients treated outside clinical trials.This was a retrospective study using MarketScan claims from January 2012 to October 2014. We included adults, newly initiated on rivaroxaban, warfarin, with baseline CHA2DS2-VASc score ≥2, ≥2 diagnosis codes for NVAF ≥180 days continuous medical prescription benefits. Patients prior stroke, systemic embolism...
Introduction: Numerous real-world studies have compared non-vitamin K antagonist oral anticoagulants (NOACs) with vitamin antagonists (VKAs) in patients non-valvular atrial fibrillation (NVAF). A meta-analysis was performed to synthesize the available evidence.Methods: Systematic searches were through 12/2016 identify non-randomized NVAF comparing NOACs VKAs, and reporting effectiveness, safety, or persistence.Results: Of 562 citations identified, 49, 79, 18 rivaroxaban, dabigatran,...
Background:Fibromyalgia is a chronic condition associated with widespread pain, sleep disturbance and disability. Disease related costs are high effective treatment options few.Objectives:To evaluate the cost effectiveness of pregabalin in fibromyalgia.Methods:A decision-analytic model was developed comparing 300 mg or 450 against placebo, duloxetine 60 120 mg, gabapentin, tramadol amitriptyline. After 12 week phase patients who responded to entered an ongoing using Markov which maintained...
Several comparative real-world effectiveness studies on direct oral anticoagulants (DOACs) have been conducted, but an overview of the available evidence remains to be developed, which could provide a better understanding value DOACs relative vitamin K antagonists (VKAs).A systematic literature review was conducted (RWE) three (rivaroxaban, dabigatran, and apixaban) compared with VKAs (e.g. warfarin), in patients nonvalvular atrial fibrillation (NVAF).This included RWE published up December...
To evaluate the cost-effectiveness of an extended (12+12 weeks) course varenicline plus brief counselling compared with currently reimbursed smoking cessation interventions (in combination counselling) in Belgium, from a public payer perspective.The previously published version BENESCO model which included was updated recent publically available demographic and cost data Belgium.The has incremental per quality adjusted life year gained 1101€ nonextended 12-week (plus counselling). The...
To describe the collective costs of vitamin K antagonist (VKA) treatment for stroke prevention in non-valvular atrial fibrillation (NVAF). VKA drug are relatively low, but they necessitate frequent international normalized ratio (INR) monitoring. There currently minimal data describing economic impact this Mexico.Cardiologists provided on their NVAF patients (n = 400) to quantify direct medical (INR testing, appointments, costs). A sub-set 301) completed a patient questionnaire providing...
Currently, 15-20% of individuals with coronary artery disease (chronic syndrome [CCS]) or peripheral (PAD) receiving routine treatment experience cardiovascular events (CVEs) within 3-4 years. Using PICOSTEPS (Patients-Intervention-Comparators-Outcomes-Setting-Time-Effects-Perspective-Sensitivity analysis) reporting, we evaluated the cost-effectiveness recently approved rivaroxaban 2.5 mg twice daily in combination acetylsalicylic acid 100 (RIV + ASA) for prevention CVEs among Finns CCS...
Vitamin K antagonists (VKAs) are used for stroke prevention in patients with non-valvular atrial fibrillation (NVAF), but necessitate regular monitoring of prothrombin time via international normalized ratio (INR) testing. This study explores the economic burden VKA therapy Russian NVAF.Cardiologists provided clinical characteristics and healthcare resource use data relating to patient's first year treatment. Data were quantify direct medical costs (INR testing, consultations, drug costs)....
Background Morbidity and mortality associated with non-valvular atrial fibrillation (NVAF) imposes a substantial economic burden on the UK healthcare system.Objectives An existing Markov model was adapted to assess real-world cost-effectiveness of rivaroxaban apixaban, each compared vitamin K antagonist (VKA), for stroke prevention in patients NVAF from National Health Service (NHS) personal social services (PSS) perspective.Methods The considered cycle length 3 months over lifetime horizon....
Real-world evidence (RWE) provides external validity, supplementing and enhancing the randomized controlled trial data with valuable information on patient behaviors outcomes, turning efficacy safety results into real-world effectiveness risks, but use of RWE is associated challenges. The objectives this communication were to (1) summarize all guidance how conduct an meta-analysis (MA) develop cost-effectiveness model, (2) describe our experience, challenges faced solutions identified, (3)...
Background Patients with stable coronary artery disease (CAD) or peripheral (PAD) are at substantial risk of atherothrombotic events. The COMPASS trial showed that patients CAD PAD experienced significant benefits after treatment rivaroxaban in combination acetylsalicylic acid (ASA) compared ASA alone. This paper aims to provide insight into the clinical and economic consequences from a Dutch societal perspective.Methods implications terms number events prevented, costs, incremental cost per...
Aims: Non-vitamin K antagonist oral anticoagulants (NOACs) and vitamin antagonists (VKAs) are used to prevent stroke in patients with atrial fibrillation (AF). This paper aimed evaluate the clinical efficacy safety of NOACs when compared VKAs by calculating number needed treat (NNT) at 2 years using incidence rates hazard ratios (HRs) derived from a meta-analysis studies conducted real-world settings. Materials methods: HRs were sourced published systematic literature review evidence on use...
Aim: To evaluate antithrombotic treatment patterns in patients Italy with nonvalvular atrial fibrillation (NVAF) before and after direct oral anticoagulants (DOACs) were approved. Methods: This analysis included a discharge diagnosis of NVAF 2010 2014, which constituted the pre- post-DOACs populations, respectively. Results: Approximately 90% eligible for anticoagulant (OAC) therapy. Overall use OACs increased from 38% to 45% 2014; antiplatelet therapy decreased 36 25%. 14% remained...
A third of non-valvular atrial fibrillation (NVAF) patients are non-adherent to direct oral anticoagulants (DOACs). Estimates the economic value full adherence and cost two types improving interventions important healthcare planners decision-makers.A cost-utility analysis estimated impact non-adherence over a 20-year horizon, for patient cohort with mean age 77 years, based on data from Stockholm Healthcare database NVAF incident stroke between 2011 2018. Adherence was defined using...